Perrigo (PRGO) Change in Receivables (2013 - 2026)
Perrigo's (PRGO) quarterly Change in Receivables came in at $92.5 million in Q1 2026, up 41.87% year-on-year from $65.2 million in Q1 2025, and up 454.41% on a QoQ basis from -$26.1 million in Q4 2025.
Perrigo (PRGO) Change in Receivables (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Change in Receivables data on file, last reported at $92.5 million in Q1 2026.
- On a quarterly basis, Change in Receivables rose 41.87% year-over-year to $92.5 million in Q1 2026; TTM through Mar 2026 was -$3.4 million, a 113.93% decrease from a year earlier, with the FY2025 full-year figure at -$30.7 million, down 376.58% from the prior year.
- Change in Receivables for Q1 2026 stood at $92.5 million, up from -$26.1 million in the prior quarter.
- Over the last five years, Change in Receivables for PRGO reached as high as $92.5 million in Q1 2026 and fell as low as -$59.3 million in Q2 2025.
- Historically, Change in Receivables has averaged $7.6 million across 5 years, with a median of -$1.9 million in 2023.
- On a YoY basis, Change in Receivables climbed as much as 2836.84% in 2024 and fell as far as 331.11% in 2024.
- Year by year, Change in Receivables stood at -$38.7 million in 2022, then soared by 65.12% to -$13.5 million in 2023, then sank by 331.11% to -$58.2 million in 2024, then surged by 55.15% to -$26.1 million in 2025, then surged by 454.41% to $92.5 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $92.5 million in Q1 2026, -$26.1 million in Q4 2025, and -$10.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 92.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 92.50 Mn |
| Mar 28, 2026 | 92.50 Mn |
| Dec 31, 2025 | -26.10 Mn |
| Dec 31, 2025 | -26.10 Mn |
| Sep 27, 2025 | -10.50 Mn |
| Sep 27, 2025 | -10.50 Mn |
| Jun 28, 2025 | -59.30 Mn |
| Jun 28, 2025 | -59.30 Mn |
| Mar 29, 2025 | 65.20 Mn |
| Mar 29, 2025 | 65.20 Mn |
| Dec 31, 2024 | -58.20 Mn |
| Dec 31, 2024 | -58.20 Mn |
| Sep 28, 2024 | 52.00 Mn |
| Sep 28, 2024 | 52.00 Mn |
| Jun 29, 2024 | -34.60 Mn |
| Jun 29, 2024 | -34.60 Mn |
| Mar 30, 2024 | 51.90 Mn |
| Mar 30, 2024 | 51.90 Mn |
| Dec 31, 2023 | -13.50 Mn |
| Dec 31, 2023 | -13.50 Mn |